Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

2.76USD
15 Dec 2017
Change (% chg)

$-0.13 (-4.50%)
Prev Close
$2.89
Open
$2.85
Day's High
$2.91
Day's Low
$2.69
Volume
9,775,424
Avg. Vol
2,254,903
52-wk High
$5.66
52-wk Low
$2.69

Latest Key Developments (Source: Significant Developments)

Achillion announces pricing of secondary offering of common stock
Wednesday, 15 Nov 2017 10:05pm EST 

Nov 15 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces pricing of secondary offering of common stock.Says secondary public offering of 18.4 million common shares priced at $2.75per share.  Full Article

Achillion announces proposed secondary offering of common stock
Tuesday, 14 Nov 2017 04:03pm EST 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion announces proposed secondary offering of common stock.Achillion Pharmaceuticals Inc says ‍intends to offer for sale in an underwritten public offering 18.4 million shares of common stock of achillion​.Achillion Pharmaceuticals - existing stockholder of company, Johnson & Johnson Innovation-JJDC Inc will be making the offering of common stock.Achillion Pharmaceuticals Inc - ‍achillion will not sell any shares or receive any proceeds from offering​.  Full Article

Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g
Tuesday, 14 Nov 2017 04:01pm EST 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc :Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g.Achillion Pharmaceuticals Inc - ‍greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ach-4471​.Achillion Pharmaceuticals Inc - ‍improvement in complement alternative pathway biomarkers observed​.Achillion Pharmaceuticals Inc - ‍preliminary data from phase 2 trial suggest that ach-4471 may reverse ap hyperactivity in c3g​.Achillion Pharma- ‍preliminary data from phase 2 trial suggest ach-4471 may have potential to reverse AP hyperactivity resulting in improvement in proteinuria​.  Full Article

Achillion says ACH-4471 granted orphan drug designation by FDA
Monday, 6 Nov 2017 06:05am EST 

Nov 6 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria.Achillion Pharma - ‍EMA committee for orphan medicinal products issued a positive opinion on ACH-4471 for orphan status in EU for treatment of PNH​.  Full Article

Achillion Q3 loss per share $0.14
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion reports third quarter 2017 financial results and provides update on clinical programs.Q3 loss per share $0.14.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

RTW Investments reports 5.2 pct passive stake in Achillion Pharmaceuticals - SEC filing‍​
Thursday, 28 Sep 2017 03:09pm EDT 

Sept 28 (Reuters) - RTW Investments LP::RTW Investments LP reports 5.2 percent passive stake in Achillion Pharmaceuticals Inc as of September 18, 2017 - SEC filing‍​.  Full Article

Achillion Pharmaceuticals says Joel Barrish plans to leave co
Monday, 10 Jul 2017 04:05pm EDT 

July 10 (Reuters) - Achillion Pharmaceuticals Inc :Achillion Pharmaceuticals Inc - ‍announced that Joel Barrish, executive vice president and chief scientific officer, plans to leave company.Achillion Pharmaceuticals Inc - Achillion continues to dose PNH patients in a phase 2 study of its first complement factor D inhibitor, ACH-4471​.Achillion Pharmaceuticals Inc - ‍ACH-4471 is also poised to begin a phase 2 clinical study in C3G​.  Full Article

Achillion Q1 loss per share $0.15
Thursday, 4 May 2017 06:05am EDT 

May 4 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion reports first quarter 2017 financial results and provides update on clinical programs.Q1 loss per share $0.15.Q1 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.  Full Article

Achillion announces initiation of patient dosing in phase 2 study of ACH-4471
Thursday, 6 Apr 2017 06:05am EDT 

Achillion Pharmaceuticals Inc : Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 for paroxysmal nocturnal hemoglobinuria . Achillion Pharmaceuticals Inc - interim results from phase 2 open-label study of ACH-4471 are anticipated during q2 of 2017 .Achillion - look forward to evaluating ACH-4471 in phase 2 trial for patients with C3 glomerulopathy that co plans initiate during H2 of this year.  Full Article

Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million
Thursday, 23 Feb 2017 05:26pm EST 

Achillion Pharmaceuticals Inc :Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million - SEC filing.  Full Article